Danicopan, sold under the brand name Voydeya, is an oral medication used as an add-on therapy for adults with paroxysmal nocturnal hemoglobinuria (PNH).
Danicopan is an oral small‑molecule complement inhibitor that targets factor D in the alternative pathway and is used for paroxysmal nocturnal hemoglobinuria (PNH), particularly to manage extravascular hemolysis in patients already on C5 blockade.
Danicopan reversibly binds complement factor D, preventing cleavage of factor B and formation of the alternative‑pathway C3 convertase (C3bBb).
This reduces complement‑mediated hemolysis and C3 fragment deposition on PNH erythrocytes.
It was approved by the [FDA] specifically to treat extravascular hemolysis (EVH), which is the breakdown of red blood cells occurring outside blood vessels.
It is used in combination with other PNH treatments like [ravulizumab (Ultomiris)] or eculizumab (Soliris) when those primary therapies are not enough to control the breakdown of red blood cells.
Danicopan is a first-in-class Factor D inhibitor. It works by blocking a specific protein in the complement system to prevent it from attacking and destroying healthy red blood cells.
By inhibiting the alternative pathway proximally, it both controls intravascular hemolysis and mitigates C3‑mediated extravascular hemolysis, while largely preserving classical and lectin pathway activity.
It is typically taken as an oral tablet three times a day (TID), approximately 8 hours apart.
Due to the risk of serious infections (specifically meningococcal infections), it is only available through a restricted distribution program called the Voydeya REMS Program.
PNH patients adding danicopan saw significant increases in hemoglobin levels and a reduced need for blood transfusions.
Common Side Effects: Some patients may experience increased liver enzymes, headaches, or gastrointestinal issues.
In phase II monotherapy studies, danicopan improved LDH, hemoglobin, bilirubin, and fatigue scores in untreated PNH, showing clinically meaningful control of hemolysis and anemia.
In PNH patients, danicopan at 150–200 mg three times daily achieved >90% inhibition of alternative‑pathway activity and reduced circulating PNH RBCs with C3 deposition by >50% when added to C5 inhibitors.
When added on to eculizumab or ravulizumab demonstrates improved hemoglobin, reduced transfusion needs, and improvements in markers of extravascular hemolysis.
Typical dosing is multiple times daily oral administration (e.g., 150–200 mg TID) with food; exact regimen follows product labeling and local regulatory guidance.
It is used chronically alongside ravulizumab or eculizumab, with monitoring of hemoglobin, LDH, bilirubin, and transfusion requirements.
Common adverse events include headache and upper respiratory tract infection in trials; gastrointestinal events and liver enzyme elevations have also been reported.
Danicopan is a Breast Cancer Resistance Protein (BCRP) inhibitor; coadministration with BCRP substrates (e.g., some statins, certain chemotherapeutics) can increase their plasma concentrations and may require dose adjustment or monitoring.